why choose us

300×250 Ad Slot

Research Article: Ocrelizumab-induced colitis—critical review and case series from a Romanian cohort of MS patients

Date Published: 2025-02-05

Abstract:
Background: Widespread use of ocrelizumab, an anti-CD20 monoclonal antibody, for treating patients with multiple sclerosis (MS), has led to an increase in reported adverse events following real-world observation. Among these, drug-induced colitis is a rare, but severe side effect, prompting a recent FDA statement regarding this safety concern. Objectives: We analyzed a cohort of ocrelizumab treated patients in our MS center to evaluate the incidence of drug-induced colitis.

No summary available.

300×250 Ad Slot